Futibatinib is a Small Molecule owned by Otsuka Pharmaceutical, and is involved in 13 clinical trials, of which 6 were completed, and 7 are ongoing.
TAS-120 is an irreversible FGFR inhibitor. It binds to and inhibits FGFR which result in the inhibition of FGFR-related signal transduction pathways. FGFR signaling regulates tissue homeostasis and is also involved in processes such as tissue repair and angiogenesis. In angiogenesis and neovascularization, FGFR signaling plays an indirect role by influencing other growth factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor. Inhibition of FGFR inhibits various downstream pathways necessary for tumor growth and may check the progression of the disease by acting on its underlying cause.
The revenue for Futibatinib is expected to reach a total of $756m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Futibatinib NPV Report.
Futibatinib (Lytgobi) is an anticancer agent. It is formulated as a film-coated tablet for oral route of administration, Lytgobi is indicated for the treatment of adult patients with previously treated, unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.
TAS-120 (futibatinib) is under development for the treatment of solid tumors including advanced or metastatic urothelial carcinoma, cholangiocarcinoma (CCA), unspecified cancer (FGFR aberrations cancer), non-small-cell lung cancer, HER2-negative metastatic breast cancer, HR positive metastatic breast cancer and triple-negative breast cancer, breast cancer, glioblastoma, anaplastic astrocytoma, anaplastic oligodendroglioma, urothelial carcinoma, metastatic gastric cancer, gastro esophageal junction cancer, metastatic hepatocellular carcinoma, metastatic microsatellite stable endometrial carcinoma, multiple myeloma, myeloid and lymphoid neoplasms. The drug candidate is administered orally. It is a small molecule acts by targeting fibroblast growth factor receptors (FGFRs).
It was also under development for squamous cell lung cancer harboring FGFR1 gene amplification.
Otsuka Holdings Overview
Otsuka Holdings (Otsuka) is a holding company, which operates various businesses such as pharmaceuticals, nutraceuticals, consumer products and other businesses through its subsidiaries. It focuses on the research and development, manufacture, and sale of medicines for the treatment of cancer, cardiovascular diseases, central nervous system disorders, ophthalmic diseases, gastrointestinal and respiratory diseases, infectious diseases, dermatological conditions and allergies. The company’s product portfolio includes pharmaceutical products, cosmetics, functional foods and beverages, alcoholic beverages, fine chemicals, electronic equipment, functional chemicals, medical devices and OTC products. It markets its products in North America, Europe, and Asia. Otsuka is headquartered in Chiyoda-ku, Tokyo, Japan.
The company reported revenues of (Yen) JPY1,498,276 million for the fiscal year ended December 2021 (FY2021), an increase of 5.3% over FY2020. In FY2021, the company’s operating margin was 10.3%, compared to an operating margin of 13.8% in FY2020. In FY2021, the company recorded a net margin of 8.4%, compared to a net margin of 10.4% in FY2020. The company reported revenues of JPY451,811 million for the third quarter ended September 2022, an increase of 4.1% over the previous quarter.
Quick View – Futibatinib
|Highest Development Stage|